

Real Life™

Gil Sambrano, PhD

Vice President, Portfolio Development and Review

CIRM Funding Model

June 2023

CIRM
CALIFORNIA'S STEM CELL AGENCY



Infrastructure

INFR



Education

EDUC



Discovery

DISC




Translation

TRAN



Clinical

CLIN



Funding Opportunities Function via an Application and Review Process



What is CIRM looking for and how do researchers partner with CIRM to achieve the mission?

Recurring Funding Opportunities Program Announcement (PA)



DISCOVERY



TRANSLATION



CLINICAL

DISC 0 Fundamental biology research (1-2 cycles per year)	TRAN1 Therapeutic candidate development	CLIN1 IND-enabling studies (12 cycles per year)
	TRAN 2 Diagnostic candidate development	
DISC 2 Quest – Product candidate discovery research (2 cycles per year)	TRAN 3 Medical device candidate development	CLIN2 Clinical trial studies (12 cycles per year)
	TRAN 4 Tool candidate development	
	(2 cycles per year)	

Non-recurring Funding Opportunities Request for Applications (RFA)




INFRASTRUCTURE



EDUCATION

INFR 4 Alpha Clinics Network	EDUC 2 Bridges Training Program
INFR 5 Manufacturing Network	EDUC 3 SPARK Training Program
INFR 6 Shared Labs Resource	EDUC 4 Research Training Program (CIRM Scholars)
	EDUC 5 COMPASS Program



CIRM Mandate:

- Research using stem and progenitor cells (and “genetic therapies”)
- Research that generally NIH and Federal Government do not support
- Development of therapies and cures (affordable and accessible)
- Allocation for diseases of the brain

Otherwise:

- No directive related to specific diseases, conditions, scientific disciplines, stage of research

Cell Therapy

Where stem or progenitor cells compose the therapy or are used to manufacture the therapy

Small Molecule or Biologic

- That acts on or is dependent on endogenous stem cells for its therapeutic effect
- That is dependent on targeting cancer stem cells for its therapeutic effect
- That modifies a stem cell therapy (e.g., imaging agent)
- Where a stem cell is necessary to manufacture the therapy

New
under
Prop 14



Genetic Therapy

That 1) alters the genomic sequence of cells or 2) that introduces or directly manipulates nucleic acids (such as mRNAs, antisense oligonucleotides) in cells.

- How can CIRM make the greatest impact on its mission?
- How narrow or how broad should the CIRM portfolio be as it relates to:
 - Disease representation
 - Qualifying candidates (e.g., cancer stem cells, progenitor cells, genetic therapies)
 - Similar therapeutic approaches (e.g., CAR T)
- How much funding support is necessary within a given therapeutic approach, stage of research, or disease to have a meaningful impact?
- What is (or what are) the most important outcomes for CIRM in 10 years?